No Data
No Data
Express News | Enanta Pharmaceuticals Inc : Evercore ISI Cuts Target Price to $30 From $35
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shareholders are probably feeling a little disappointed, since its shares fell 8.3% to US$12.76 in the week after its latest quarterly results. Revenue
Enanta Pharmaceuticals | 10-Q: Quarterly report
Hold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial Outlook
Enanta Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
Enanta Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
Buy Rating Affirmed for Enanta Pharmaceuticals Amidst Promising RSV Developments and Clinical Trial Execution